-
Dec 10, 2024 | 
bioprocessonline.com | Antony Hitchcock |AGH Bioconsulting |Junwei Sun |Lucia Fernandez |Lucia Fernández
Let Us Handle Your Buffer PreparationThermo Fisher Scientific is here to support you with the buffer preparation in your manufacturing workflow. Leaving the non-core activities to us enables you to focus on the patient therapy development. Our capabilities cover off-the-shelf products like WFI, NaOH, NaCl, or EtOH, a library of the most frequently used buffers that are made-to-order, as well as fully customized buffers.
-
Dec 10, 2024 | bioprocessonline.com | Antony Hitchcock |AGH Bioconsulting |Junwei Sun |Lucia Fernandez |Lucia Fernández
Let Us Handle Your Buffer PreparationThermo Fisher Scientific is here to support you with the buffer preparation in your manufacturing workflow. Leaving the non-core activities to us enables you to focus on the patient therapy development. Our capabilities cover off-the-shelf products like WFI, NaOH, NaCl, or EtOH, a library of the most frequently used buffers that are made-to-order, as well as fully customized buffers.
-
Dec 2, 2024 | 
cellandgene.com | Antony Hitchcock |AGH Bioconsulting |R.k. DeLong
Webinar: Leveraging Platform Processes for Developing and Accelerating Novel Gene and Cancer TherapeuticsThe FDA's new draft guidance for the Platform Technology Designation Program helps drug developers leverage platform data to speed approvals and improve patient access. In an upcoming webinar, experts will discuss platform processes, supply chain integration, and share insights on combining AAV gene therapy with cytokine immunotherapy to treat cancer. Click here to learn more.
-
Nov 19, 2024 | 
cellandgene.com | Antony Hitchcock |AGH Bioconsulting
By Antony Hitchcock, principal and owner, AGH Bioconsulting
It goes without saying that the last two years have been challenging for the whole of the biotechnology sector, with widespread layoffs and reduced investment in the sector.
-
Sep 20, 2024 | 
cellandgene.com | Laura Keita |Philip Ross |Antony Hitchcock |AGH Bioconsulting
Tessera Therapeutics' CEO, Dr. Michael Severino, joins Host Erin Harris to discuss Gene Writing, the biotech's genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Severino discusses why delivery has always been a challenge for gene editing technologies and why Gene Writing is different when it comes to efficient delivery. Better Audits, Faster Through Transparency And EfficiencyClinical trial audits are evolving.
-
Aug 14, 2024 | 
advancingrna.com | AR Welch |Advancing RNA |Antony Hitchcock |AGH Bioconsulting
In the first- of this three-part article series, several mRNA execs share their perspectives on the world of partnering in the RNA therapeutics space, assessing first the current state of CDMO partnerships and how they anticipate this critical supportive infrastructure will grow in the years ahead. FDA's draft guidance on platforms is mostly for established, well-characterized modalities, but it also has implications for the emerging area of personalized medicine.
-
Aug 6, 2024 | 
outsourcedpharma.com | Louis Garguilo |Antony Hitchcock |AGH Bioconsulting |Alex Klarer
Not really into choosing extended time away and exhibit halls over the simple pleasures of summertime? No reason to put your CDMO search on hold – Outsourced Pharma Capacity Update’s PARTNER WEEK is now available on-demand. Take the travel and headache out of your plans and tune in right from your computer. Assess potential fit for your next drug development project in convenient 20-minute segments – all grouped by molecule type.
-
Jul 31, 2024 | 
advancingrna.com | Kimberly Benton |Antony Hitchcock |AGH Bioconsulting |Louis Garguilo
There’s been great progress in establishing platforms for linear mRNA vaccines — but where does this current know-how fall short for those exploring linear and next-gen RNA constructs for non-vaccine products? Secure your spot for Advancing RNA Live’s next digital panel discussion on the current known unknowns (and unknown unknowns) about our mRNA therapeutics candidates that make adopting the traditional QbD approach complicated. Registration is free thanks to the support of Roche Custom Biotech.
-
Jul 17, 2024 | 
cellandgene.com | Antony Hitchcock |AGH Bioconsulting |A. Navarro |S. Maestro
FDA's draft guidance on platforms is mostly for established, well-characterized modalities, but it also has implications for the emerging area of personalized medicine. Preparing For FDA Pre-Approval Inspection: Quality And Regulatory TopicsConsider these strategies for meeting quality and regulatory requirements in cell and gene therapies that can also help to identify issues early, reduce risks, and prevent delays and rework.
-
Jul 15, 2024 | 
bioprocessonline.com | Antony Hitchcock |AGH Bioconsulting |Sewon Park |Yingji Jin
Connect with researchers from around the world for a deep dive into solutions for optimizing bioprocessing, and immerse yourself at the forefront of innovation at CHI's Bioprocessing Summit. Leaders from top pharma, biotech, academic, and governmental institutions will convene on August 19-22 in Boston and online for cutting-edge presentations, live breakout groups, poster sessions, collaboration, networking, and more. Learn more at BioprocessingSummit.com.
